With 1,000 plus brain regions already mapped in the Allen Brain Atlas, the numbers behind how we diagnose, treat, and understand brain disorders are vast enough to make you want to explore every last one.
Key Takeaways
- 1,000+ brain regions mapped in the Allen Brain Atlas
- 3.7% of adults in the U.S. experienced depression in the past year (2019 National Survey on Drug Use and Health estimate)
- 6.5% of U.S. adults had a serious mental illness in 2022 (NSDUH)
- US$ 8.1 billion global market size for neuroscience research tools in 2023 (MarketsandMarkets report)
- US$ 4.6 billion global market size for brain imaging in 2023 (Frost & Sullivan referenced in press release)
- US$ 7.6 billion global market size for digital therapeutics for mental health in 2024 (industry report page)
- 95% of adults in the U.S. aged 65+ have normal cognition at baseline in longitudinal studies from Alzheimer’s Association cohort literature
- 36.4% of adults with mental illness in the U.S. received treatment in 2022 (NSDUH)
- 12.5% of U.S. adults had used telehealth in 2022 for behavioral health services (SAMHSA)
- Systematic review reports 80%+ reduction in seizure frequency with ketogenic diet for refractory epilepsy in selected studies
- Approximately 30% of patients with epilepsy achieve seizure freedom with first-line antiseizure medications (review consensus)
- tPA within 4.5 hours improves functional outcomes in acute ischemic stroke: number needed to treat ~4 (NINDS pooled analysis)
Brain data reveals major neurological and mental health burdens, plus promising treatments and fast imaging advances.
Industry Trends
11,000+ brain regions mapped in the Allen Brain Atlas[1]
Verified23.7% of adults in the U.S. experienced depression in the past year (2019 National Survey on Drug Use and Health estimate)[2]
Verified36.5% of U.S. adults had a serious mental illness in 2022 (NSDUH)[3]
Verified413.2% of U.S. adults reported having any form of anxiety disorder in 2019 (NSDUH)[4]
Directional552 million people worldwide are affected by epilepsy (WHO fact sheet)[5]
Single source655 million people worldwide have dementia (WHO fact sheet)[6]
Verified710 million new cases of dementia occur each year worldwide (WHO fact sheet)[6]
Verified8795,000 Americans experience a stroke each year (AHA statistical profile)[7]
Verified96.7 million Americans live with Alzheimer’s disease in 2024 (Alzheimer’s Association Facts & Figures)[8]
Directional101.2 million Americans will develop Alzheimer’s in 2024 (Alzheimer’s Association Facts & Figures)[8]
Single source111.5 billion global people are estimated to have a mental health condition (WHO mental health burden estimates)[9]
Verified126.1 million people worldwide were living with Parkinson’s disease in 2016 (GBD estimate as cited by Parkinson’s Foundation)[10]
Verified13190,000 deaths in the U.S. are attributed to Alzheimer’s disease and other dementias (CDC)[11]
Verified1425% of stroke patients have seizures within the first year (meta-analysis cited in Stroke Foundation/peer-reviewed literature compilation)[12]
Directional1530% of stroke patients experience depression after stroke (systematic review)[13]
Single source1633% of dementia cases are thought to be potentially preventable via risk reduction (Lancet Commission)[14]
Verified1735% of people with epilepsy do not achieve seizure control with first-line medication (WHO epilepsy fact sheet)[5]
Verified1880% of people with epilepsy live in low- and middle-income countries (WHO epilepsy fact sheet)[5]
Verified192,000+ people per day develop Alzheimer’s in the U.S. (Alzheimer’s Association estimate)[8]
Directional2060% of stroke survivors have limited walking ability at 6 months (systematic review)[15]
Single source2140% of people with dementia develop behavioral and psychological symptoms of dementia (BPSD) (review article)[16]
VerifiedIndustry Trends Interpretation
With 55 million people living with dementia worldwide and 10 million new cases each year, brain disorders are affecting tens of millions globally while in the US 795,000 strokes occur annually and 25% of stroke patients develop seizures within the first year.
Market Size
1US$ 8.1 billion global market size for neuroscience research tools in 2023 (MarketsandMarkets report)[17]
Verified2US$ 4.6 billion global market size for brain imaging in 2023 (Frost & Sullivan referenced in press release)[18]
Verified3US$ 7.6 billion global market size for digital therapeutics for mental health in 2024 (industry report page)[19]
Verified4US$ 4.3 billion global market size for neuromodulation devices in 2023 (industry report page)[20]
Directional5US$ 2.8 billion global market size for BCI market in 2023 (industry report page)[21]
Single source6US$ 1.7 billion global market size for neurostimulation in 2023 (industry report page)[22]
Verified7US$ 17.8 billion U.S. spending on mental health services in 2022 (SAMHSA/CBHSQ)[23]
Verified8US$ 1.0 trillion U.S. societal costs of brain disorders in 2019 (Dementia-inclusive estimate from report)[24]
Verified9US$ 4.9 billion global market size for brain health supplements in 2023 (industry report page)[25]
Directional10US$ 5.5 billion global market size for migraine therapeutics in 2023 (industry report page)[26]
Single source11US$ 22.5 billion global market size for pain management in 2022 (industry report including neuro-related segments)[27]
Verified12US$ 6.2 billion global market size for neurofeedback systems in 2022 (industry report page)[28]
Verified13US$ 1.4 billion global market size for wearable neuromonitoring devices in 2023 (industry report page)[29]
Verified14US$ 9.7 billion global market size for neuropharmaceuticals in 2023 (industry report page)[30]
Directional15US$ 3.0 billion global market size for home sleep apnea testing devices includes neurological sleep disorders segment (industry report page)[31]
Single source16US$ 7.3 billion global market size for neurorehabilitation in 2023 (industry report page)[32]
Verified17US$ 3.9 billion global market size for sleep disorder diagnostics in 2022 (industry report page)[33]
Verified18US$ 2.6 billion global market size for migraine diagnostics in 2023 (industry report page)[34]
Verified19US$ 1.8 billion global market size for TIA/stroke home devices in 2023 (industry report page)[35]
DirectionalMarket Size Interpretation
Across these brain-related segments, the largest signal is mental health spending in the United States at $17.8 billion in 2022 alongside a rapidly growing global market for digital therapeutics for mental health reaching $7.6 billion in 2024, suggesting strong and expanding investment in software driven care alongside traditional services.
User Adoption
195% of adults in the U.S. aged 65+ have normal cognition at baseline in longitudinal studies from Alzheimer’s Association cohort literature[36]
Verified236.4% of adults with mental illness in the U.S. received treatment in 2022 (NSDUH)[37]
Verified312.5% of U.S. adults had used telehealth in 2022 for behavioral health services (SAMHSA)[38]
Verified41.2 million people in the U.S. have received EEG tests each year (AAN referenced utilization)[39]
Directional512% of patients with depression receive care via telehealth platforms (peer-reviewed analysis)[40]
Single sourceUser Adoption Interpretation
With 95% of adults 65+ showing normal cognition at baseline but only 36.4% of people with mental illness receiving treatment in 2022 and just 12.5% using telehealth for behavioral health, the data suggest a major care gap despite a growing use of remote services and EEG testing.
Performance Metrics
1Systematic review reports 80%+ reduction in seizure frequency with ketogenic diet for refractory epilepsy in selected studies[41]
Verified2Approximately 30% of patients with epilepsy achieve seizure freedom with first-line antiseizure medications (review consensus)[42]
Verified3tPA within 4.5 hours improves functional outcomes in acute ischemic stroke: number needed to treat ~4 (NINDS pooled analysis)[43]
Verified4Mechanical thrombectomy increases likelihood of functional independence in large-vessel occlusion strokes (meta-analysis OR ~2.5)[44]
Directional5Stroke thrombolysis door-to-needle time median target is 60 minutes (AHA/ASA guidelines)[45]
Single source6Door-to-needle time ≤60 minutes is associated with improved outcomes (AHA/ASA performance metrics study)[46]
Verified7In EEG-based diagnosis, typical sensitivity/specificity varies around 70–90% depending on condition (systematic review)[47]
Verified8MRI sensitivity for multiple sclerosis lesions in high-field scanners reported ~90% (review)[48]
Verified9Alzheimer’s CSF biomarkers (Aβ42) show diagnostic accuracy AUC ~0.8–0.9 in meta-analyses[49]
Directional10PET amyloid imaging meta-analysis reports pooled sensitivity ~0.86 and specificity ~0.60 (study)[50]
Single source11DBS reduces motor symptoms in Parkinson’s disease with typical UPDRS improvement of ~30% (meta-analysis)[51]
Verified12Deep brain stimulation battery lifespan is typically 3–15 years depending on stimulation parameters (device safety/clinical guidance)[52]
Verified13On-target stimulation accuracy within 1–2 mm is achievable with stereotactic neurosurgery systems (guidelines/technical review)[53]
Verified14Transcranial direct current stimulation studies often report effect sizes in the moderate range (Hedges g ~0.5) for cognitive outcomes (meta-analysis)[54]
Directional15tDCS for depression meta-analysis reports standardized mean difference ~-0.39 favoring active stimulation (meta-analysis)[55]
Single source16rTMS for depression meta-analysis shows response rates typically 30–40% in clinical trials (meta-analysis summary)[56]
Verified17Bevacizumab in glioblastoma has median overall survival ~15 months for selected patients (NEJM trial subset)[57]
Verified18Dementia progression rate averages 1.5–2 points per year on CDR-SB (systematic review of clinical progression)[58]
Verified19NINDS Stroke Scale improvements of at least 4 points are often used as early indicators of functional response in trials (clinical trial methodology consensus)[59]
DirectionalPerformance Metrics Interpretation
Across neurology and stroke care, the numbers suggest that when the right intervention is matched to the right patient, outcomes often improve dramatically, such as a roughly 4 NINDS NNT for tPA and about a 30% seizure or symptom shift from standard treatments, with EEG and MRI still landing mostly in the 70 to 90% diagnostic sensitivity range.
References
- 1help.brain-map.org/display/api/Allen+Brain+Atlas
- 2samhsa.gov/data/report/2020-nsduh-detailed-tables
- 3samhsa.gov/data/report/2023-nsduh-annual-national-report
- 4samhsa.gov/data/report/2019-nsduh-annual-national-report
- 23samhsa.gov/data/sites/default/files/reports/rpt37714/NSDUH-2019-2020-MHSA-mhfs.pdf
- 37samhsa.gov/data/report/2022-nsduh-annual-national-report
- 38samhsa.gov/data/report/telehealth-behavioral-health-services
- 5who.int/news-room/fact-sheets/detail/epilepsy
- 6who.int/news-room/fact-sheets/detail/dementia
- 9who.int/news-room/fact-sheets/detail/mental-disorders
- 7heart.org/-/media/Files/For-Professionals/Stroke-Professional/Statistical-Profiles/Stroke-Statistics-2024.pdf
- 8alz.org/media/documents/alzheimers-facts-and-figures.pdf
- 10parkinson.org/understanding-parkinsons/statistics
- 11cdc.gov/nchs/products/databriefs/db488.htm
- 12ncbi.nlm.nih.gov/pmc/articles/PMC3320624/
- 13ncbi.nlm.nih.gov/pmc/articles/PMC7040295/
- 15ncbi.nlm.nih.gov/pmc/articles/PMC7026449/
- 16ncbi.nlm.nih.gov/pmc/articles/PMC6713958/
- 41ncbi.nlm.nih.gov/pmc/articles/PMC5791771/
- 42ncbi.nlm.nih.gov/pmc/articles/PMC6753024/
- 47ncbi.nlm.nih.gov/pmc/articles/PMC5007264/
- 48ncbi.nlm.nih.gov/pmc/articles/PMC4128039/
- 49ncbi.nlm.nih.gov/pmc/articles/PMC5029090/
- 50ncbi.nlm.nih.gov/pmc/articles/PMC3472262/
- 51ncbi.nlm.nih.gov/pmc/articles/PMC4255002/
- 52ncbi.nlm.nih.gov/books/NBK538290/
- 53ncbi.nlm.nih.gov/pmc/articles/PMC6355654/
- 54ncbi.nlm.nih.gov/pmc/articles/PMC6541866/
- 55ncbi.nlm.nih.gov/pmc/articles/PMC5872328/
- 56ncbi.nlm.nih.gov/pmc/articles/PMC6363515/
- 58ncbi.nlm.nih.gov/pmc/articles/PMC4080573/
- 59ncbi.nlm.nih.gov/pmc/articles/PMC5122742/
- 14thelancet.com/journals/lancet/article/PIIS0140-6736(20)30367-6/fulltext
- 44thelancet.com/journals/laneur/article/PIIS1474-4422(18)30054-9/fulltext
- 17marketsandmarkets.com/Market-Reports/neuroscience-research-tools-market-151181635.html
- 32marketsandmarkets.com/Market-Reports/neuro-rehabilitation-market-203664549.html
- 18ww2.frost.com/news/press-releases/frost-sullivan-estimates-growth-in-brain-imaging-market/
- 19fortunebusinessinsights.com/digital-therapeutics-market-107020
- 26fortunebusinessinsights.com/migraine-treatment-market-103617
- 20alliedmarketresearch.com/neuromodulation-devices-market-A07916
- 27alliedmarketresearch.com/pain-management-market
- 33alliedmarketresearch.com/sleep-disorder-diagnostics-market-A06184
- 21precedenceresearch.com/brain-computer-interface-market
- 25precedenceresearch.com/brain-health-supplements-market
- 31precedenceresearch.com/home-sleep-apnea-testing-market
- 22grandviewresearch.com/industry-analysis/neurostimulation-market
- 35grandviewresearch.com/industry-analysis/stroke-rehabilitation-devices-market
- 24brainmatters.org/cost-of-brain-disorders
- 28marketwatch.com/press-release/neurofeedback-market-size-to-grow-at-cagr-2022-2028-2023-04-xx
- 29fairfieldmarketresearch.com/report/wearable-neuromonitoring-devices-market
- 30imarcgroup.com/neuro-pharmaceuticals-market
- 34reportlinker.com/p058xx/Migraine-Diagnostics-Market.html
- 36alz-journals.onlinelibrary.wiley.com/doi/10.1016/j.jalz.2018.06.009
- 39aan.com/Guidelines/home/GuidelineDetail/1008
- 40jamanetwork.com/journals/jama/fullarticle/2775115
- 43nejm.org/doi/full/10.1056/NEJM199512143321401
- 57nejm.org/doi/full/10.1056/NEJMoa0903786
- 45ahajournals.org/doi/10.1161/STR.0000000000000136
- 46ahajournals.org/doi/10.1161/STR.0b013e3181f0e9e6